We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Celgene Strikes $78M Deal In Elan Abraxane IP Suit

Law360 (February 24, 2011, 10:18 PM EST) -- Elan Pharma International Ltd. and Celgene Corp. announced a $78 million settlement Thursday that ends four years of litigation over breast cancer drug Abraxane, which allegedly infringed two patents held by...
To view the full article, register now.